NextCure reports Q1 EPS (61c), consensus (46c)

Cash, cash equivalents, and marketable securities as of March 31 were $96M as compared to $108.3M as of December 31 . The decrease of $12.3Mwas primarily due to cash used to fund operations. NextCure expects financial resources to fund operating expenses and capital expenditures into the second half of 2026.”We look forward to providing an update on the NC410 combo trial at the ASCO Annual Meeting, which will include data from the additional colorectal patients enrolled earlier this year,” said Michael Richman, NextCure’s president and chief executive officer. “LNCB74, our B7-H4 ADC program, is advancing to a planned IND submission by year-end. GLP toxicology studies have been initiated and clinical material is being produced.”